Envision Pharma Group’s Post

Dive into our latest blog, where Kyle Felmet and Riparian LLC's Jennifer Lospinoso discuss transformative strategies and key considerations that are shaping the commercialization of cell and gene therapies (CGT). Their analysis covers the rapid advancements in CGT, the strategic planning required for successful market entry, and the innovative distribution models that ensure these groundbreaking treatments reach patients effectively. https://bit.ly/4boUaQl

Great summary and insight! Starting early is key to developing the critical partnerships needed for a successful launch.

Bring your questions to our upcoming roundtable—one of a three-part series—around key opportunities, scientific innovation and insights in driving acceleration of preclinical gene therapy programs to IND/CTA and beyond. Register for the roundtable. #CellTherapy #GeneTherapy #PrecisionMedicine

In our final roundtable—the last in a three-part series—we discuss considerations for incorporating #CompanionDiagnostic strategies into the development of cell and gene therapies. #CellTherapy #GeneTherapy #PrecisionMedicine #CDx

In our final roundtable—the last in a three-part series—we discuss considerations for incorporating #CompanionDiagnostic strategies into the development of cell and gene therapies. #CellTherapy #GeneTherapy #PrecisionMedicine #CDx

In our final roundtable—the last in a three-part series—we discuss considerations for incorporating #CompanionDiagnostic strategies into the development of cell and gene therapies. #CellTherapy #GeneTherapy #PrecisionMedicine #CDx

In our final roundtable—the last in a three-part series—we discuss considerations for incorporating #CompanionDiagnostic strategies into the development of cell and gene therapies. #CellTherapy #GeneTherapy #PrecisionMedicine #CDx

In our final roundtable—the last in a three-part series—we discuss considerations for incorporating #CompanionDiagnostic strategies into the development of cell and gene therapies. #CellTherapy #GeneTherapy #PrecisionMedicine #CDx

In our final roundtable—the last in a three-part series—we discuss considerations for incorporating #CompanionDiagnostic strategies into the development of cell and gene therapies. #CellTherapy #GeneTherapy #PrecisionMedicine #CDx

In our final roundtable—the last in a three-part series—we discuss considerations for incorporating #CompanionDiagnostic strategies into the development of cell and gene therapies. #CellTherapy #GeneTherapy #PrecisionMedicine #CDx